Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.

Michel, P; Adenis, A; Di Fiore, F; Boucher, E; Galais, M P; Dahan, L; Mirabel, X; Hamidou, H; Raoul, J L; Jacob, J H; Hellot, M F; Prod'homme, S; Paillot, B

Michel, P; Adenis, A; Di Fiore, F; Boucher, E; Galais, M P; Dahan, L; Mirabel, X; Hamidou, H; Raoul, J L; Jacob, J H; Hellot, M F; Prod'homme, S; Paillot, B.

Affiliation

Michel P; Unité d'oncologie digestive, Service d'Hepato-Gastroenterologie, CHU de Rouen, 1 rue de Germont 76031 Rouen Cedex, France. pierre.michel@chu-rouen.fr

Br J Cancer ; 95(6): 705-9, 2006 Sep 18.

Article in En | MEDLINE | ID: mdl-16967056

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Camptothecin / Esophageal Neoplasms / Carcinoma, Squamous Cell / Antineoplastic Combined Chemotherapy Protocols / Cisplatin Type of study: Clinical_trials / Etiology_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2006 Document type: Article Affiliation country: Francia Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google